Castle Biosciences announced new data from its TissueCypher Barrett’s Esophagus test at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting in Phoenix, Arizona. The data, presented in three posters during the meeting (October 27‑29, 2025), demonstrate that TissueCypher provides risk insights beyond pathology alone, influencing clinical management and enabling earlier intervention for high‑risk patients while reducing unnecessary procedures for low‑risk patients.
The study, led by Dr. Horvath and colleagues and presented under the title “Risk‑Aligned Management of Barrett’s Esophagus Using TissueCypher Spatial Omics,” received a Presidential Poster Award—an honor awarded to only 5‑7% of accepted abstracts for high‑quality research. The poster reported that TissueCypher identified high‑risk patients in 93% of a cohort of 114 rural non‑dysplastic Barrett’s esophagus (NDBE) patients, leading to a change in surveillance strategy in 93% of cases.
Additional data presented in the other two posters showed that TissueCypher identified patients with a five‑year progression probability of 34‑62%, well above the 5‑10% risk associated with high‑grade dysplasia, who would otherwise have been managed with standard surveillance intervals. The test’s objective, individualized risk information supports personalized surveillance and intervention strategies, potentially improving patient outcomes and reducing healthcare costs.
Castle Biosciences’ announcement underscores the continued clinical validation of its spatial omics technology and its impact on patient care. The new findings are expected to strengthen adoption among gastroenterologists and may influence payer coverage decisions, building on the company’s Advanced Diagnostic Laboratory Test (ADLT) status from CMS and its ongoing expansion of the TissueCypher portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.